KALAMAZOO, Michigan — Armune BioScience, which is developing protein-based diagnostic tests for certain cancers, added $400,000 through debt and other securities, according to a filing with the Securities and Exchange Commission.
The funding follows a $1.1 million angel round the 1-year-old startup closed in August 2008. Soon after that round the company opened a research lab at the Medical Research Institute in Ann Arbor.
Armune is developing a test to detect cancer by finding evidence of the immune response to cancer. Its first product tests for prostate cancer, but it is also developing lung and breast-cancer tests.
Among the company’s investors is Apjohn Group. It has received money from the Michigan Pre-Seed Capital Fund.
Susan G Komen Race for the Cure: Here’s how it can survive
Artificial immune cell treatment for melanoma aims for human trials in 2013
Topical drug for inflammatory skin conditions banks on natural, safe profile
Sign up for MedCity News' e-newsletter, providing medical industry news from across the country.
Sign up
Anyone can blog on MedCity News when they become a "MedCitizen." MedCitizens publish their own thoughts about current medical news and the latest issues in healthcare to the entire MedCity News audience.
Amy SiegelHow low can you go? Creating value with cheap medical devices
Steven M. Auvil (Sponsored)5 things med tech companies need to know about the Leahy-Smith America Invents Act
Jim TateEscape Hatch for Electronic Submission of CQMs for Meaningful Use
Lisa Suennen2012 JP Morgan Healthcare’s (wo)men’s club is changing in a good way
Joe HageA huge American opportunity waiting to happen
Doug MowenMed tech consolidation brings a need for focus. Here are 2 ways to get it
Comments
Post a comment
No comments yet.
Post a Comment